Glyx Therapeutics https://validator.w3.org/feed/docs/rss2.html Glyx Therapeutics Joins Spartners by Servier & BioLabs Glyx Therapeutics Awarded the French Tech Emergence Deeptech Grant Glyx Therapeutics Selected as a Finalist of the i-Lab 2026 Innovation Competition Green Chemistry at Glyx Therapeutics: Join Us at the Sustainable Day in Amiens on November 5, 2026 Glyx Therapeutics at the Morning Session “Financing Your Innovation: From Idea to Market” Glyx Therapeutics Joins the Brain&Mind Community Glyx Therapeutics and SATT Nord Make Their Exclusive License Official, and Glyx Features in the Regional Media About Us HAS Refuses Early Access to Lecanemab in France: What It Means for Tau-Directed Innovation Marking World Alzheimer’s Day: Advancing the Fight Against Tauopathies Glyx Therapeutics to Attend Deeptech Connect 2025 in Paris Glyx Therapeutics to Attend BioFIT 2025 in Strasbourg Chemical Research Tauopathies Alzheimer’s Disease Contact Us Investors Glyx Therapeutics Biotech Targeting tau. Preserving the mind. Research Glyx Therapeutics to Participate in the 6th Trinational HealthTech Days Pipeline Our Team Privacy Policy blog